In a previous study we have shown that monoclonal antibody F1 (MoAb F1), directed against an epitope on the heavy chain of factor XII distinct from the binding site for anionic surfaces, is able to activate factor XII in plasma (Nuijens JH, et al: J Biol Chem 264; 12941, 1989). Here, we studied in detail the mechanism underlying the activation of factor XII by MoAb F1 using purified proteins. Formation of factor XIIa was assessed by measuring its amidolytic activity towards the chromogenic substrate H-D-Pro-Phe-Arg-pNA (S-2302) in the presence of soybean trypsin inhibitor and by assessing cleavage on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Upon incubation with MoAb F1 alone, factor XII was auto-activated in a time-dependent fashion, activation being maximal after 30 hours. Factor XII incubated in the absence of MoAb F1 was hardly activated by kallikrein, whereas in the presence of MoAb F1, but not in that of a control MoAb, the rate of factor XII activation by kallikrein was promoted at least 60-fold. Maximal activation of factor XII with kallikrein in the presence of MoAb F1 was reached within 1 hour. This effect of kallikrein on the cleavage of factor XII bound to MoAb F1 was specific because the fibrinolytic enzymes plasmin, urokinase, and tissue-type plasminogen activator could not substitute for kallikrein. Also, trypsin could easily activate factor XII, but in contrast to kallikrein, this activation was independent of MoAb F1. SDS-PAGE analysis showed that the appearance of amidolytic activity correlated well with cleavage of factor XII. MoAb F1-induced activation of factor XII in this purified system was not dependent on the presence of high- molecular-weight kininogen (HK), in contrast to the activation of the contact system in plasma by MoAb F1. Experiments with deletion mutants revealed that the epitopic region for MoAb F1 on factor XII is located on the kringle domain. Thus, this study shows that binding of ligands to the kringle domain, which does not contribute to the proposed binding site for negatively charged surfaces, may induce activation of factor XII. Therefore, these findings point to the existence of multiple mechanisms of activation of factor XII.
Skip Nav Destination
ARTICLES|
December 1, 1995
Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein
DM Ravon,
DM Ravon
Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Search for other works by this author on:
F Citarella,
F Citarella
Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Search for other works by this author on:
YT Lubbers,
YT Lubbers
Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Search for other works by this author on:
B Pascucci,
B Pascucci
Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Search for other works by this author on:
CE Hack
CE Hack
Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Search for other works by this author on:
Blood (1995) 86 (11): 4134–4143.
Citation
DM Ravon, F Citarella, YT Lubbers, B Pascucci, CE Hack; Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood 1995; 86 (11): 4134–4143. doi: https://doi.org/10.1182/blood.V86.11.4134.bloodjournal86114134
Download citation file:
December 1 1995
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal